Argenx Signs a Worldwide License Agreement with Halozyme for its ENHANZE Technology

 Argenx Signs a Worldwide License Agreement with Halozyme for its ENHANZE Technology

Argenx Signs a Worldwide License Agreement with Halozyme for its ENHANZE Technology

Shots:

  • Halozyme to receive $30M upfront, $160M milestones, $10M per future target nominations and royalties on sales of products. Argenx to get an exclusive license for Halozyme’s ENHANZE technology targeting ARGX-113 and additional two human neonatal Fc receptors (FcRn)  
  • The focus of this ninth agreement b/w the companies, is to develop and commercialize neonatal Fc receptors with SC delivery, utilizing Halozyme’s ENHANZE technology for severe autoimmune disease
  • Halozyme’s ENHANZE is a drug delivery technology based on recombinant human hyaluronidase enzyme (rHuPH20) used for reducing the need for multiple injections, health care practitioner time and time for drug administration


Click here  to read full press release/ article | Ref: Argenx | Image:The Pharmaletter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post